Regeneron Pharmaceuticals, Inc.

REGN: NasdaqGS
51Total

Lowest reading is at 21 out of 100. All scores are out of 100.

About The Company

CEO

Dr. Leonard S. Schleifer M.D., Ph.D.

Market Cap

81.13 Billion USD

Sector

Healthcare

Website

https://www.regeneron.com

Last Update

26/09/2026, 10:12:23

Description

Regeneron Pharmaceuticals, Inc.

Read More

Strongest readings

  • ✔Financial health is strong (health score 92 out of 100)
  • ✔Debt is low at 0.06 times equity
  • ✔Altman-Z score of 7.52 sits above the distress range
  • ✔Price-to-earnings of 16.8 is below the market average of 19.6
  • ✔Share count has been falling at 0.56% per year

Weakest readings

  • ✘Returns on capital have declined over five years (22.32% lower)
  • ✘The current price sits above estimated fair value (margin of safety -60.21%)
  • ✘Earnings and cashflow growth is weak (growth score 37 out of 100)

Key Figures

StatusMetricValueReadingMarket avg
✔
Price / earnings (TTM)
16.79x
19.60x
✘
Margin of safety (DCF)
-60.21%
17.95%
✘
Revenue growth (5y average)
7.76%
10.97%
✘
Dividend yield (TTM)
0.47%
1.85%
✔
Share count, per year
-0.56%
0.00%
✘Return on capital employed9.89%
10.00%

The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

Valuation

21 / 100

Priced above the market on most measures.

StatusMetricValueReadingMarket avg
✔
Price / earnings
16.79x
19.60x
Free cashflow yieldN/A4.70%
✘Price / earnings growth3.16x
1.50x
Price / book2.51x
—
✘
Margin of safety
-60.21%
17.95%

The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

  • ✘Estimated intrinsic value of 313.55 USD is below the current price of 788.04 USD

Desired Margin Of Safety

0%

▼

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Estimated Fair Value: 352.1 USD ✘

Current Price: 788 USD

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated fair value for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel for the impact this has on longterm investment returns and find a margin of safety you are comfortable with.

Growth

37 / 100

Growing more slowly than the market on most measures.

StatusMetricValueReadingMarket avg
✘
Revenue growth
7.76%
10.97%
✘Earnings growth5.31%
14.48%
Cashflow growthN/A12.35%

The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

  • ✔Revenue growth has improved this year (14.02% against a five year average of 7.76%)
  • ✔Earnings growth has improved this year (17.56% against a five year average of 5.31%)

Health

92 / 100

Balance sheet covers its obligations.

Measured on Leverage and capital, Funding and liquidity, Earnings quality.

StatusMetricValueReadingThreshold
✔Altman-Z score7.52
3.00
✔Piotroski score6.00
5.00
✔Debt / equity0.06x
0.80x
✔Current ratio4.13x
1.00x
✔Interest coverage81.69x
2.50x
✘Free cashflow / debt0.00x
0.15x
✔Debt / capital0.06x
1.00x

The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

    Dividend

    46 / 100

    Cover is thin on at least one measure.

    StatusMetricValueReadingMarket avg
    ✘
    Dividend yield
    0.47%
    1.85%
    Dividend growthN/A0.00%
    ✔Payout ratio (earnings)7.76%
    40.00%
    Payout ratio (cashflow)N/A65.00%
    Worst year, last 5 yearsN/A-2.00%

    The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

      Management

      56 / 100

      Returns on capital are at or above the market.

      StatusMetricValueReadingMarket avg
      ✘Return on equity14.41%
      15.00%
      ✘Return on capital employed9.89%
      10.00%
      Return on assets11.11%
      —
      Free cashflow return on capitalN/A—
      ✘Return on capital, 5y change-22.32%
      0.00%
      ✔
      Share count, per year
      -0.56%
      0.00%
      ✔Share count, recent-3.31%
      0.00%
      ✘Realized buyback return-85.43%
      0.00%
      ✔Goodwill erosion / equity0.00%
      2.00%
      Price volatility, 5 year30.29%
      —

      The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

      • ✘Shares were repurchased while the value score was only 21 out of 100

      Analysts

      not enough data
      StatusMetricValueReadingNeutral
      Analyst opinion scoreN/A50

      The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.

      Financial History

      Annual figures across the full reporting history we hold.

      Market Peers

      REGN

      SEC Filings

      Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

      See 35+ Years Annual Reports

      Other Information

      Company Name

      Regeneron Pharmaceuticals, Inc.

      Currency

      USD

      Beta

      0.193

      Vol Avg

      747565

      Ceo

      Dr. Leonard S. Schleifer M.D., Ph.D.

      Cik

      0000872589

      Cusip

      Exchange

      NasdaqGS

      Full Time Employees

      15410

      Industry

      Biotechnology

      Sector

      Healthcare

      Ipo Date

      Address

      777 Old Saw Mill River Road

      City

      Tarrytown

      State

      NY

      Country

      United States

      Zip

      10591-6707

      Phone

      914 847 7000

      Analysis Last Updated

      26/09/2026, 10:12:23

      Financial data compiled from SEC EDGAR filings and Yahoo Finance.

      Noticed an error with something on our site?

      Data, not advice. Do your own diligence.

      We Use Cookies